Front Endocrinol (Lausanne). 2023 Nov 2;14:1272112. doi: 10.3389/fendo.2023.1272112. eCollection 2023.
3
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.